EVMN — Evommune, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2044725 ·
Last close
$7.02
Market Cap
$290.28M
52W High
$33.20
52W Low
$4.94
ADV30
920,359
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -33,326,000 | -30,877,000 | 278,298,000 | 47,570,000 | 26,930,000 |
| Jun 2026 | 0 | — | -34,895,000 | -32,246,000 | 301,947,000 | 60,034,000 | 24,361,000 |
| Mar 2026 | 0 | — | -23,954,000 | -21,674,000 | 322,455,000 | 48,318,000 | 17,900,000 |
| Dec 2025 | 0 | — | -29,716,000 | -28,273,000 | 224,946,000 | 44,063,000 | 19,380,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,153,000
Investing CF
$-200,872,000
Financing CF
$274,217,000
CapEx
$-370,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.37
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-275,009,000
Inventory
—
Receivables
—
ST Investments
$140,759,000
EBIT TTM
$-101,893,000
Pretax Income TTM
$-94,668,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-120,125,000
Free Cash Flow
$-49,564,500
Enterprise Value
$155,053,424
Total Cash
$168,638,000
Total Debt
$8,192,000
Shares Out
41,349,860
Trailing EPS
$-3.83
Book Value
$6.91
ROE
-69.5%
ROA
-42.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,000,000 | -81,071,000 | -68,870,000 | 224,946,000 | 19,380,000 | 205,566,000 | -76,441,000 |
| Dec 2024 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$301,947,000
Forward EPS
$-3.47
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $6.88 · call volume: 31 · put volume: 25
Expected Move to 2027-02-19:
±$3.85
(55.96%) —
implied range
$3.03 –
$10.73
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EBS | Emergent BioSolutions Inc. | $288.44M | $5.61 | — |
| GALT | GALECTIN THERAPEUTICS INC | $293.47M | $2.91 | — |
| MPLT | MapLight Therapeutics, Inc. | $286.78M | $6.57 | — |
| FULC | Fulcrum Therapeutics, Inc. | $286.43M | $3.75 | — |
| VCRE | Vicore Pharma Holding AB | $285.02M | $10.12 | — |
News headlines (Yahoo Finance, 1h cache)
Evommune to Present at Upcoming Investor Conferences
2026-11-09 13:05 · Yahoo
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
2026-11-07 04:14 · Yahoo
Evommune signs $1.1bn licence deal with Hinova for EVO570
2026-11-05 11:36 · Yahoo
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
2026-11-05 11:30 · Yahoo
Evommune Announces $30 Million Private Placement
2026-11-04 22:10 · Yahoo
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
2026-11-04 22:02 · Yahoo
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Ne
2026-10-19 17:00 · Yahoo
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
2026-10-01 12:00 · Yahoo
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
2026-09-23 20:05 · Yahoo
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
2026-09-16 19:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.